Microparticles prepared from biodegradable polyhydroxyalkanoates as matrix for encapsulation of cytostatic drug

详细信息    查看全文

• 作者：A. V. Murueva (1) (2)
  E. I. Shishatskaya (1) (2)
  A. M. Kuzmina (2)
  T. G. Volova (1) (2)
  A. J. Sinskey (3) (4) (5)
  
• 刊名：Journal of Materials Science Materials in Medicine
• 出版年：2013
• 出版时间：August 2013
• 年：2013
• 卷：24
• 期：8
• 页码：1905-1915
• 全文大小：747KB
• 参考文献：1. Dutta RC. Drug carriers in pharmaceutical design: promises and progress. Curr Pharm Des. 2007;13:761-. i.org/10.2174/138161207780249119">CrossRef
  2. Freiberg S, Zhu X. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282:1-8. i.org/10.1016/j.ijpharm.2004.04.013">CrossRef
  3. Jain K. Drug delivery systems—an overview. In: Jain KK, editor. Drug delivery systems. USA: Humana Press; 2009. p. 1-0.
  4. Volova TG. Microbial polyhydroxyalkanoates—plastic materials of the 21st century (biosynthesis, properties, applications). NY: Nova Science Pub. Inc.; 2004. p. 282.
  5. Volova TG, Sevastianov VI, Shyshatskaya EI. Polyhydroxyalkanoates—biodestructible polymers for medicine. Krasnoyarsk: Platina; 2006. p. 288.
  6. Sudesh K, Abe H, Doi Y. Synthesis, structure and properties of polyhydroxyalkanoates: biological polyesters. Prog Polym Sci. 2000;25:1503-5. i.org/10.1016/S0079-6700(00)00035-6">CrossRef
  7. Ueda H, Tabata Y. Polyhydroxyalkanonate derivatives in current clinical applications and trials. Adv Drug Deliv Rev. 2003;55:501-8. i.org/10.1016/S0169-409X(03)00037-1">CrossRef
  8. Salman MA, Sahin A, Onur MA. Tramadol encapsulated into polyhydroxybutirate microspheres: in vitro release and epidural analgetic effect in rats. Acta Anaesthesiol Scand. 2003;47:1006-2. i.org/10.1034/j.1399-6576.2003.00180.x">CrossRef
  9. Lionzo M, Re M, Guterres S. Pohlmann microparticles prepared with poly(hydroxybutyrate-co-hydroxyvalerate) and poly(ε-caprolactone) blends to control the release of a drug model. J Microencapsul. 2007;24:175-6. i.org/10.1080/02652040701233556">CrossRef
  10. Bazzo G, et al. Effect of preparation conditions on morphology, drug content and release profiles of poly(hydroxybutyrate) microparticles containing piroxicam. J Braz Chem Soc. 2008;19:914-1. i.org/10.1590/S0103-50532008000500016">CrossRef
  11. Bidone J, et al. Preparation and characterization of ibuprofen-loaded microspheres consisting of poly(3-hydroxybutyrate) and metoxy poly (ethylene glycol)-b-poly (is type-small-caps">d , is type-small-caps">l -lactide) blends or poly(3-hydroxybuturate) and gelatine composites for controlled drug release. Mater Sci Eng. 2009;29:588-3. i.org/10.1016/j.msec.2008.10.016">CrossRef
  12. Zawidlak-Wegrzyńska B, et al. Synthesis and antiproliferative properties of ibuprofen–oligo(3-hydroxybutyrate) conjugates. Eur J Med Chem. 2010;45:1833-2. i.org/10.1016/j.ejmech.2010.01.020">CrossRef
  13. Lu B, Wang ZR, Yang H. Long-acting delivery microsheres of levo-norgesterol- poly(3-hydroxybutirate): their preparation, characterization and contraceptive tests on mice. J Microencapsul. 2001;18:55-4. i.org/10.1080/026520401750038601">CrossRef
  14. Rossi S, Azghani A, Omri A. Antimicrobal efficacy of a new antibiotic-loaded poly(hydroxybutyric-co-hydroxyvaleric acid) controlled release system. J Antimicrob Chem. 2004;54:1013-. i.org/10.1093/jac/dkh477">CrossRef
  15. Duran N, et al. Microencapsulation of antibiotic rifampicin in poly(3-hydroxybutyrate-co3- hydroxyvalerate). Arch Pharm Res. 2008;31:1509-6. i.org/10.1007/s12272-001-2137-7">CrossRef
  16. Zhang C, et al. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur J Pharm Biopharm. 2010;76:10-. i.org/10.1016/j.ejpb.2010.05.005">CrossRef
  17. Shishatskaya EI, Chlusov IA, Volova TG. A hybrid PHA-hydroxyapatite composite for biomedical application: production and investigation. J Biomater Sci Polym Ed. 2006;17(5):481-8. i.org/10.1163/156856206776986242">CrossRef
  18. Shishatskaya EI. Biomedical investigation, application of PHA. Macromol Symp. 2008;269:65-1. i.org/10.1002/masy.200850909">CrossRef
  19. Livshits VA, Bonartsev AP, Iordansky AL. Microspheres poly(3-hydroxybutyrate) for prolonged release of drugs. Vysokomol Soedin. 2009;51:1243-1 (in Russian).
  20. Goreva AV, Shishatskaya EI, Volova TG. Characterization of polymeric microparticles based on resorbable polyesters of oxyalkanoic acids as a platform for deposition and delivery of drugs. Vysokomol Soedin. 2012;54(2):224-6 (in Russian).
  21. Nakaoka R, Tsuchiya T. Biocompatibility of various kinds of polymeric microspheres estimated from their effect on gap junctional intercellular communication of fibroblasts. Mater Trans. 2002;43(12):3122-. i.org/10.2320/matertrans.43.3122">CrossRef
  22. Soppimatha KS, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1-0. i.org/10.1016/S0168-3659(00)00339-4">CrossRef
  23. Vasil’ev E, et al. Transdermal therapeutic systems for controlled drug release. Khim Farm Zh. 2001;35(11):29-2 (in Russian).
  24. Maia L, Santana M. The effect of some processing conditions on the characteristics of biodegradable microspheres obtained by an emulsion solvent evaporation process. Braz J Chem Eng. 2004;21:1-2. i.org/10.1590/S0104-66322004000100002">CrossRef
  25. Embelton JK, Tighe BJ. Polymers for biodegradable medical devices. X: microincapsulation studies: control of polyhydroxybutyrate-hydroxyvalerate microcapsule porosity via polycaprolactone blending. Biomaterials. 1993;10(3):341-2.
  26. Khang G, et al. Preparation and characterization of poly(3-hydroxybutirate-co-3-hydroxyvalerate) microspheres for the sustained release of 5-fluorouracil. Biomed Mater Eng. 2001;11:89-03.
  27. Huang W, et al. A novel PHBV/HA microsphere releasing system loaded with alendronate. Mater Sci Eng. 2009;29:2221-. i.org/10.1016/j.msec.2009.05.015">CrossRef
  28. Lu X, et al. Sustained release of PI3?K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines. Appl Microbiol Biotechnol. 2011;89:1423-3. i.org/10.1007/s00253-011-3101-1">CrossRef
  29. Shah M, et al. Amphiphilic PHA-mPEG copolymeric nanocontainers for drug delivery: preparation, characterization and in vivo evaluation. Inter J Pharm. 2010;400:165-5. i.org/10.1016/j.ijpharm.2010.08.008">CrossRef
  30. Yu JJ, et al. Biodistribution and anti-tumor efficacy of PEG/PLA nanoparticles loaded doxorubicin. J Drug Target. 2007;15(4):279-4. i.org/10.1080/10611860701357235">CrossRef
  31. de Sanchez Juan B. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. J Drug Target. 2006;14(9):614-2. i.org/10.1080/10611860600866872">CrossRef
  32. Lee Y, et al. MMPs-specific PEGylated peptide–DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm. 2007;67:646-4. i.org/10.1016/j.ejpb.2007.03.023">CrossRef
  33. Furgenson D, Dreher M, Chilkoti A. Structural optimization of a “smart-doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. J Control Release. 2006;110:362-. i.org/10.1016/j.jconrel.2005.10.006">CrossRef
  34. Cheng X, et al. DNA/chitosan nanocomplex as a novel drug carrier for doxorubicin. Drug Deliv. 2009;16:135-4. i.org/10.1080/10717540802605376">CrossRef
  35. Kim J, Kabanov A, Bronich T. Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. J Control Release. 2009;138:197-04. i.org/10.1016/j.jconrel.2009.04.019">CrossRef
  36. Lee H, Chang J. Preparation, characterization and in vitro release of gentamicin from PHBV/wollastonite composite microspheres. J Control Release. 2005;107:463-3. i.org/10.1016/j.jconrel.2005.05.019">CrossRef
  
• 作者单位：A. V. Murueva (1) (2)
  E. I. Shishatskaya (1) (2)
  A. M. Kuzmina (2)
  T. G. Volova (1) (2)
  A. J. Sinskey (3) (4) (5)
  
  1. Institute of Biophysics SB RAS, Akademgorodok 50, Krasnoyarsk, 660036, Russia
  2. Institute of Modern Biology and Biotechnology, Siberian Federal University, Svobodny Av. 79, Krasnoyarsk, 660041, Russia
  3. Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
  4. Engineering Systems Division, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
  5. Health Sciences Technology Division, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
  

文摘

Microparticles made from degradable polyhydroxyalkanoates of different chemical compositions a homopolymer of 3-hydroxybutyric acid, copolymers of 3-hydroxybutyric and 4-hydroxybutyric acids (P3HB/4HB), 3-hydroxybutyric and 3-hydroxyvaleric acids (P3HB/3HV), 3-hydroxybutyric and 3-hydroxyhexanoic acids (P3HB/3HHx) were prepared using the solvent evaporation technique, from double emulsions. The study addresses the influence of the chemical compositions on the size and ξ-potential of microparticles. P3HB microparticles loaded with doxorubicin have been prepared and investigated. Their average diameter and ξ-potential have been found to be dependent upon the level of loading (1, 5, and 10?% of the polymer mass). Investigation of the in vitro drug release behavior showed that the total drug released from the microparticle into the medium increased with mass concentration of the drug. In this study mouse fibroblast NIH 3T3 cells were cultivated on PHA microparticles, and results of using fluorescent DAPI DNA stain, and MTT assay showed that microparticles prepared from PHAs of different chemical compositions did not exhibit cytotoxicity to cells cultured on them and proved to be highly biocompatible. Cell attachment and proliferation on PHA microparticles were similar to those on polystyrene. The cytostatic drug encapsulated in P3HB/3HV microparticles has been proven to be effective against HeLa tumor cells.